Flint Congressman Kildee Questions Lead Treatment Drug Price Hike, Calls for Investigation
Some would say the convenient, hefty price hike on a lead exposure treatment drug is suspicious in the wake of the Flint Water Crisis garnering National attention.
Mlive is reporting that Rep. Dan Kildee is questioning the price increase on Valeant Pharmaceuticals' Calcium Disodium Versenate, a drug that is used for treatment of lead exposure. The company increased the price of this drug from $900 to $27,000 per treatment.
Rep. Dan Kildee has sent a letter to Congressional leaders in the House Committee on Oversight and Government Reform and House Committee on Energy and Commerce urging them to investigate the 'shocking price increase'.
The pharmaceutical company continues to claim that the drug is not an appropriate treatment for the lead exposure cases found in Flint and defends that the price increase is a way to keep the drug in stock and limit the amount being purchased so there is a constant supply available.